Simcere Wins NMPA Nod to Start Clinical Trials for Novel EGFR/cMET Cancer Drug

Submitted by Anonymous on

The latest update is out from Simcere Pharmaceutical Group Limited ( ($HK:2096) ). Simcere Pharmaceutical Group Limited has received approval from China’s National Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools...

Clinicopathologic features and therapeutic outcomes in EGFR/ALK-aberrations NSCLC with histologic transformation

Submitted by Anonymous on

AbstractBackground The aim of this study is to delineate clinicopathologic features, therapeutic outcomes, and tumor microenvironment (TME) remodeling in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor/anaplastic lymphoma kinase (EGFR/ALK) aberrations who experience histologic transformation (HT), with...

In-silico studies, synthesis, and pharmacological screening of novel multitarget diphenylpyrazole scaffold as EGFR/BRAF and cyclooxygenase-2 inhibitors

Submitted by Anonymous on

Multi-targeting drug design has become a prevalent attitude in exploring effective potent anticancer agents. In this regard, cyclooxygenase II (COX 2), tubulin, and focal adhesion kinase (FAK) are emerging as highly effective targets in the battle against cancer. Pyrazoles AS-(1–16)...

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

Submitted by Anonymous on

Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to support potential accelerated and full regulatory approvals NEWTOWN SQUARE, Pa., Dec. 22, 2025 (GLOBE NEWSWIRE)...

FDA Approves Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer

Submitted by Anonymous on

HORSHAM, P.A. (December 17, 2025) – Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), the first and only subcutaneously (SC) administered therapy for patients with epidermal growth...

Network Pharmacology and Experimental Validation Reveal Aidi Injection Suppresses Prostate Cancer via EGFR Inhibition and STAT3-Mediated Apoptosis

Submitted by Anonymous on

AbstractBackground Prostate cancer (PCa) is the most common male reproductive malignancy, with traditional Chinese medicine (TCM) offering potential complementary treatments. Aidi injection, used for liver, lung, and colorectal cancers, shows promise for PCa, but its mechanisms are unclear. This study...

Subscribe to Newsfeed